文献速递糖尿病

2型糖尿病患者使用长效注射或口服胰高血糖素样肽1受体激动剂的心血管与肾脏结局及死亡率:随机试验的系统综述与Meta分析

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
PubMed 文献 · Diabetes Care · 2025-01-01

该系统综述与Meta分析纳入10项随机安慰剂对照试验(n=71,351),评估长效GLP-1RA在2型糖尿病中的心血管与肾脏获益及安全性。结果显示长效GLP-1RA降低主要不良心血管事件(MACE)发生率14%(HR 0.86)、心力衰竭住院14%(HR 0.86)、复合肾脏结局17%(HR 0.83)和全因死亡12%(HR 0.88),且皮下与口服给药途径间无显著异质性,未增加严重低血糖、视网膜病变或胰腺事件风险。

要点

  • 长效GLP-1RA降低2型糖尿病患者MACE发生率14%(HR 0.86 [95% CI 0.81, 0.90])。
  • 复合肾脏结局降低17%(HR 0.83 [95% CI 0.75, 0.92]),全因死亡降低12%(HR 0.88 [95% CI 0.82, 0.93])。
  • 皮下与口服给药途径间疗效无显著异质性,未增加严重低血糖、视网膜病变或胰腺事件风险。

核心结论

  • 长效GLP-1RA(包括注射和口服制剂)作为一类药物,可降低2型糖尿病患者MACE、心力衰竭住院、肾脏事件的发生率和全因死亡率。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed至2025年2月7日,纳入10项随机安慰剂对照心血管和肾脏结局试验,共n=71,351例2型糖尿病患者,使用随机效应模型估计风险比(HR)。

主要发现

  • 长效GLP-1RA降低MACE发生率14%(HR 0.86 [95% CI 0.81, 0.90];I²=27.6%)。
  • 降低心力衰竭住院14%(HR 0.86 [95% CI 0.79, 0.93];I²=2.1%)。
  • 降低复合肾脏结局17%(HR 0.83 [95% CI 0.75, 0.92];I²=20.4%)。
  • 降低全因死亡率12%(HR 0.88 [95% CI 0.82, 0.93];I²=17.5%)。
  • 所有MACE组分均显示一致的14%降低;按给药途径(皮下 vs 口服)无显著异质性;未增加严重低血糖、视网膜病变或胰腺事件风险。

关键数值与推荐

  • 长效GLP-1RA定义为药代动力学足以提供24小时活性的制剂。
  • 复合肾脏结局包括肾衰竭(肾脏替代治疗或持续性eGFR<15 mL/min/1.73 m²)、持续性eGFR下降≥50%或最接近等效指标、或肾脏相关死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验水平的Meta分析无法进行详细的亚组分析,并可能引入生态学偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE: In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, we examined cardiovascular (CV) and kidney benefits and risks of long-acting (defined as having pharmacokinetics sufficient to provide 24-h activity) GLP-1RA in T2D. DATA SOURCES: A systematic review of PubMed was conducted (to 7 February 2025). STUDY SELECTION: Randomized placebo-controlled CV and kidney outcomes trials of GLP-1RA with ≥500 individuals with T2D were included. DATA EXTRACTION: A random-effects model was used to estimate hazard ratios (HRs) for MACE, its components, all-cause mortality, hospitalization for heart failure (HHF), a composite kidney outcome (kidney failure [kidney replacement therapy or persistent estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m2], sustained ≥50% eGFR decline or nearest equivalent, or kidney-related death), worsening kidney function, and safety outcomes. DATA SYNTHESIS: Across 10 trials (n = 71,351), long-acting GLP-1RA reduced incidence rate of MACE by 14% (HR 0.86 [95% CI 0.81, 0.90]; I2 = 27.6%), HHF by 14% (0.86 [0.79, 0.93]; I2 = 2.1%), and the composite kidney outcome by 17% (0.83 [0.75, 0.92]; I2 = 20.4%) and all-cause mortality by 12% (0.88 [0.82, 0.93]; I2 = 17.5%). A consistent 14% reduction was seen for all MACE components. There was no significant heterogeneity by GLP-1RA administration route (subcutaneous vs. oral). There were no increased risks of severe hypoglycemia, retinopathy, or pancreatic events. LIMITATIONS: Trial-level meta-analyses preclude detailed subgroup analyses and may introduce ecological bias. CONCLUSIONS: As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lee MMY, Sattar N, Pop-Busui R, et al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 2025. PMID: 40156846. doi:10.2337/dc25-0241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。